How to Make the Most of ISPOR Vienna with RTI Health Solutions

Share on: 

Deepen your understanding of current topics with one of these workshops led by our experts

Workshop W1: The New NICE Cancer Drugs Fund Technology Appraisal Process: Your Questions Answered. Boysen, M; Tyas, D; Ling, C; Wolowacz, S

In the UK, the provision of new oncology drugs by the National Health Service has been a contentious issue for a number of years. Because the CDF has been restructured this year, understanding the new operating model and its implementation is key. “We’ll be talking about how drugs are identified as suitable for inclusion, how the committee approaches decision making, and what implications the new requirement will have on data collection.” –Caroline Ling, PhD, Senior Director, Market Access and Outcomes Strategy at RTI-HS.

Workshop W2: Moving the Science Forward: Psychometric Considerations and Study Designs for Understanding Meaningful Change and Conducting Mixed Methods Research. Hudgens, S; Symonds, T; McLeod, L; Coon, C

A panel of measurement specialists was convened to consider two issues identified as challenging in the context of developing, evaluating, and interpreting data from COA tools. This workshop will outline the issues and describe the panel discussions that took place, noting areas of agreement and where additional research is needed. Attendees will be encouraged to share their perspectives—as well as provide insight gained from their own research—to move toward scientific consensus.

Workshop W12: Rethinking What Missing Patient-reported Outcome (PRO) Data Can Teach Us About Outcomes and Survival in Oncology Clinical Trials. Boye, M; Houghton, K; Stull, D

“The FDA and many HTA bodies are increasingly putting pressure on pharma to prove alongside a clinical survival benefit, that patients also show a PRO benefit. Until now, the analytic approaches used in the face of all the missing data were generally lacking. The type of results this method produces may well satisfy the requirements for evidence of both clinical and patient-perceived improvement.” —Katherine Houghton, Associate Director of Health Economics at RTI-HS 

Workshop W13: Changing Our Perspective on Patient-reported Outcomes in Oncology: It's More Complex Than Traditionally Conceptualized or Analyzed. Boye, M; Stull, D; Ainsworth, C

Standard analytic approaches often fail to take into account the more complex causal pathways between treatment, symptoms, and outcomes of functioning and quality of life. Researchers at RTI-HS and Eli Lilly are using sophisticated methods of structural equation modeling to show that significant relationships do exist. “These path analytic approaches we’re using have been available for more than half a century but are seldom used in analyses of clinical trial data. Their advantage is their ability to show how a treatment or symptom change affects HRQL.” —Donald Stull, Head of Data Analytics and Design Strategy at RTI-HS 

Workshop W14: Choice Defines Value: How to Analyse and Disseminate Evidence on the Importance of Multiple Criteria From Multiple Perspectives to Inform an Appraisal Process in Health Technology Assessment. Craig, B; Muhlbacher, A; Gonzalez, JM; Ramos-Goni, JM

Through audience engagement and demonstration, this workshop will give attendees a hands-on understanding of the underlying issues surrounding MCDA. The presenters will demonstrate the analysis, interpretation and dissemination of the results of a live MCDA that was conducted during a workshop at the ISPOR 21st Annual International Meeting using a hand-held response system. Following a hands-on exercise, the presenters will introduce examples and open discussion for questions and concerns regarding MCDA. 


Related Services:
Staff Members: